26 april, 2021
AcuCort AB (Spotlight Stock Market: ACUC) has employed Louise Harting as Project Manager. The company has entered a new stage in the preparatory work for the upcoming commercialization and thus needs a dedicated and expanded resource. Louise has taken up the new position with a focus on market registration of the drug ISICORT®.
Louise Harting holds a master degree (M.Sc.) in International Business from Copenhagen Business School. She has experience of international product launches in the pharmaceutical industry from, among others, Novo Nordisk. In her role as Project Manager at AcuCort, her responsibilities include applications for market registration of ISICORT® in the Nordic region and Europe.
“It is very gratifying that we now have Louise on board as Project Manager. With Louise in place together with Mats Lindfors, former CEO of AcuCort who has many years’ experience of international product launches, including the US, and who today is one of our key consultants, and our production and regulatory partners, we have managed to build a strong team in preparation for the commercialization of ISICORT®. I look forward to the next phase in the company’s development,” says Jonas Jönmark, CEO of AcuCort AB.
ISICORT® is a thin, fast-dissolving and user-friendly oral film approved in Sweden for among other things for the treatment of acute and severe allergic reactions, for croup in children, chemotherapy-induced nausea and vomiting (CINV), as well as for the treatment of covid-19 patients who need supplemental oxygen treatment. The fast-dissolving oral film contains the glucocorticoid dexamethasone, which is a well-known, often used and well-documented anti-inflammatory substance.
The information was submitted for publication, through the agency of the contact person below, on April 26, 2021.
For more information, please contact:
Jonas Jönmark, CEO, AcuCort AB
Telephone: + 46 (0)70 365 5400
About AcuCort AB (publ)
AcuCort develops and commercializes ISICORT®, a new fast-dissolving oral film to put on the tongue, based on a well-known cortisone substance – dexamethasone. ISICORT® is a smart product in a new, innovative, patented and user-friendly dosage form primarily for the treatment of severe and acute allergic reactions, croup in children and chemotherapy-induced nausea and vomiting (CINV). A national application was approved by the Swedish Medical Products Agency (MPA) in October 2020. In February 2021, ISICORT® was granted an additional indication – the treatment of COVID-19 patients who need supplemental oxygen treatment. Altogether, this strengthens the company’s assessment that the time to commercialization of ISICORT® may be relatively short. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market in Sweden. Please visit www.acucort.com.